Aurora Cannabis Inc. vs Amylyx Pharmaceuticals, Inc. — Valuation Comparison 2026
Access all valuation models for ACB vs AMLX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →ACB scores higher with a 6.9/10 quality rating vs AMLX's 5.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Aurora Cannabis Inc. (ACB) and Amylyx Pharmaceuticals, Inc. (AMLX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
ACB currently trades at $3.67 with a QOC of 6.9/10, while AMLX trades at $14.22 with a QOC of 5.9/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).